Read: A Real and Present Threat to Alzheimer's Patients

A Real And Present Threat To Alzheimer's Patients

RealClearHealth | June 18, 2025 | Wayne Winegarden

It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments.

Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging its authority to determine which medical technologies patients can access.

This is a tragedy playing out for people with Alzheimer’s disease.

Newt Gingrich: Pay Less, Know More

Fox News | June 4, 2025 | Newt Gingrich

One of the boldest and most consistent themes in President Donald J. Trump’s healthcare agenda is his determination to reduce the role and power of middlemen...

PBMs – giant corporations that control which drugs are covered and at what cost – use their market power to inflate prices. Three PBMs control 80 percent of the market. They’re often subsidiaries of major insurers, forming vertically integrated monopolies. New data from the Pacific Research Institute shows that most PBMs skim more money off high-cost prescriptions than European countries charge. It’s no wonder Americans are paying more.

Don't Believe The CBO's Spin On The One Big Beautiful Bill Act

Washington Examiner | June 18, 2025 | Sally C. Pipes

In a recent letter to top Democrats, the Congressional Budget Office claimed that the Republicans’ One Big Beautiful Bill Act would kick millions of people off their health insurance. That warning is misleading.

Millions of people are improperly enrolled in Medicaid and taxpayer-subsidized plans through Obamacare’s exchanges. Republicans are rightly trying to bring some integrity to these programs and ensure that only those needy individuals who are eligible for publicly funded health coverage under the law can claim it.